Page 95 - Sitomegalovirüs Tanı, Tedavi Uzlaşı Raporu

17. Eres-Sarıtaş Z. Yenidoğanlarda konjenital cytomegalovirus (CMV) enfeksiyonu
görülme sıklığının araştırılması. Tıpta Uzmanlık Tezi. 2013, Antalya.
18. Sahiner F, Cekmez F, Cetinkaya M, Kaya G, Kalayci T, Gunes O, Sener K, Yapar M,
Tunc T, Ecemis T, Cekmez Y, Kubar A. Congenital cytomegalovirus infections and
glycoprotein B genotypes in live-born infants: a prevalence study in Turkey. Infect Dis
(Lond). 2015;47(7):465-71.
19. Zeytinoğlu A, Terek D, Arslan A, Erensoy S, Altun Köroğlu Ö, Bozdemir T, Yalaz M,
Ergör SN, Öğüt MF, Kültürsay N. Investigation of congenital CMV infection with the
presence of CMV DNA in saliva samples of new born babies. Mikrobiyol Bul.
2019;53(1):53-60.
20. Bilavsky E, Watad S, Levy I, Linder N, Pardo J, Ben-Zvi H, Attias J, Amir J. Positive
IgM in Congenital CMV Infection. Clin Pediatr (Phila). 2017;56(4):371-375.
21. Kraft CS, Armstrong WS, Caliendo AM. Interpreting quantitative cytomegalovirus
DNA testing: understanding the laboratory perspective. Clin Infect Dis.
2012:54(12):1793-7.
22. Delforge ML, Desomberg L, Montesinos I. Evaluation of the new LIAISON CMV IgG,
IgM and IgG Avidity II assays. J Clin Virol. 2015;72:42-45.
23. Lagrou K, Bodeus M, Van Ranst M, Goubau P. Evaluation of the new architect
cytomegalovirus immunoglobulin M (IgM), IgG, and IgG avidity assays. J Clin
Microbiol. 2009;47(6):1695-1699.
24. Hizel S, Parker S, Onde U. Seroprevalence of cytomegalovirus infection among
children and females in Ankara, Turkey, 1995. Pediatr Int. 1999;41(5):506-509.
25. Torre-Cisneros J, Aguado JM, Caston JJ et al. Management of CMV Infection in Solid
Organ Transplant Recipients: SET/GESITRA-SEIMC/REIPI recomendations.
Transplant Rev(Orlando). 2016;30(3):119-143.
26. Pillay D, Ali AA, Liu SF, et al. The Prognostic Significance of Positive CMV Cultures
During Surveillance of Renal Transplant Recipients. Transplantation. 1993;56(1):103-
108.
27. Kotton CN, Kumar D, Calliende AM et al. Updated international consensus guidelines
on the management of CMV in solid organ transplantation. Transplantation.
2013;96(4):333-360.
28. Preiksaitis JK, Sandhu J, Strautman M. The risk of transfusion acquired CMV
infection in seronegative solid organ transplant recipients recieving non-WBC
reduced blood components not screened for CMV antibody (1984-1996): experience
at a single Canadian center. Transfusion. 2002;42(4):396-402.
29. Lisboa LF, Asberg A, Kumar D, et al. The clinical utility of whole blood versus plasma
CMV viral load assays for monitoring therapeutic response. Transplantation.
2011;91:231-236.
30. Fryer JF, Heath AB, Minor PD; Collaborative Study Group. A collaborative study to
establish the 1st WHO International Standart for human CMV(HCMV) for nucleic acid
amplification (NAT) techonology. Biologicals. 2016;44(4):242-251.
31. Preiksaitis JK, Hayden RT,Tong Y et al. Are We There Yet? Impact of the First
International Standart For CMV DNA on the Harmonization of Results Reported on
Plasma Samples. Clin Infect Dis. 2016;63:583-589.
32. Hayden RT, Sun Y, Tang L et al. Progress in Quantitative Viral Load Testing:
Variability and Impact of the WHO Quantitative International Standarts. J Clin
Microbiol. 2017;55:423-430.

92